---
title: Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)
nct_id: NCT05532904
overall_status: COMPLETED
phase: NA
sponsor: Assistance Publique - Hôpitaux de Paris
study_type: INTERVENTIONAL
primary_condition: Post COVID-19 Condition
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05532904.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05532904"
ct_last_update_post_date: 2026-03-05
last_seen_at: "2026-05-12T06:41:09.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)

**Official Title:** Evaluation and Comparison of Multidisciplinary Day-hospital Versus Waiting List Management of Persistent Symptoms After an Acute Episode of COVID-19

**NCT ID:** [NCT05532904](https://clinicaltrials.gov/study/NCT05532904)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 80
- **Lead Sponsor:** Assistance Publique - Hôpitaux de Paris
- **Collaborators:** URC-CIC Paris Descartes Necker Cochin
- **Conditions:** Post COVID-19 Condition
- **Start Date:** 2023-01-18
- **Completion Date:** 2025-06-13
- **CT.gov Last Update:** 2026-03-05

## Brief Summary

After an acute episode of COVID-19, many patients experience persistent or recurrent symptoms with substantial impairment of their quality of life. The most common symptoms are fatigue, dyspnea, cognitive impairment and pain, but symptoms of all types have been reported. The heterogeneity of symptoms and their potential pathophysiology makes individualized and multidisciplinary management essential.

The primary objective of this study is to evaluate the change in quality of life at 6 months in patients with persistent symptoms after an acute episode of COVID-19 after 6 weeks of personalized multidisciplinary outpatient management versus usual care.

## Detailed Description

After an acute episode of COVID-19, many patients experience persistent or recurrent symptoms with substantial impairment of their quality of life. The most common symptoms are fatigue, dyspnea, cognitive impairment, and pain, but symptoms of all types have been reported. The heterogeneity of symptoms and their potential pathophysiology makes individualized and multidisciplinary management essential.

The primary objective is to evaluate the change in quality of life at 6 months in patients with persistent symptoms after an acute episode of COVID-19 after 6 weeks of personalized multidisciplinary outpatient management versus usual care. The secondary objectives are to evaluate the evolution of the quality of life at 3 months, the evolution of the main persistent symptoms (fatigue, dyspnea, cognitive complaints, pain), the patients' satisfaction, the predictive and explanatory factors of the evolution.

This is a prospective randomized open-label study in two parallel arms: personalized multidisciplinary outpatient intervention versus usual care (waiting list). This 6-week program of care will include:

* group education sessions including a psycho-education component (1 session / week)
* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test
* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): group cognitive and behavior therapy (2 sessions per week, including at least 1 in person).
* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Having had an initial episode of symptomatic COVID-19 according to one of the following criteria:

  * SARS-Cov-2 PCR +
  * SARS-Cov-2 + antigenic test
  * SARS-Cov-2 + serology
  * Prolonged anosmia/ageusia of sudden onset
  * Typical chest CT scan
* Still having at least one of the initial symptoms and possibly new symptoms including fatigue, dyspnea, cognitive impairment or pain beyond 4 weeks after the onset of the acute phase of the disease.
* These initial and persistent symptoms are not better explained by another diagnosis not known to be related to Covid-19.
* These symptoms are the cause of an alteration in quality of life and global functioning deemed significant by the patient.
* Having an indication to either supervised exercise and / or cognitive behavior therapy and / or cognitive remediation Exclusion Criteria
* Medical emergency requiring management not compatible with research
* Neuropsychiatric disorder likely to alter cognitive functions, prior to the Covid-19 episode
* Medical contraindication to exercise training such as pericarditis or progressive myocarditis
* Patient under state medical assistance
* Patient who does not speak French
* Pregnancy in progress
```

## Arms

- **Intervention** (OTHER) — This 6-week program of care will include:

* group education sessions including a psycho-education component (1 session / week)
* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.
* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).
* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)
- **Control** (NO_INTERVENTION) — Usual care (waiting list)

## Interventions

- **Personalized multidisciplinary day-hospital intervention** (BEHAVIORAL) — This 6-week program of care will include:

* group education sessions including a psycho-education component (1 session / week)
* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.
* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).
* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)

## Primary Outcomes

- **Quality of life** _(time frame: at 6 Months)_ — SF-12 global score - 12-item Short Form Survey (SF-12) is a general health questionnaire. Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12)

## Secondary Outcomes

- **Quality of life** _(time frame: at 3 Months)_
- **Fatigue** _(time frame: at 3 months, 6 months)_
- **Dyspnea** _(time frame: at 3 months, 6 months)_
- **Cognitive complaint** _(time frame: at 3 months, 6 months)_
- **Pain** _(time frame: at 3 months, 6 months)_
- **Patient's satisfaction** _(time frame: at 3 months, 6 months)_
- **Physical fitness** _(time frame: at inclusion, 3 months, 6 months)_
- **Post-effort heart rate** _(time frame: at inclusion, 3 months, 6 months)_
- **Weight loss** _(time frame: at inclusion, 3 months, 6 months)_
- **BMI** _(time frame: at inclusion, 3 months, 6 months)_
- **Blood albumin** _(time frame: at inclusion, 3 months, 6 months)_
- **Nutritional risk** _(time frame: at inclusion, 3 months, 6 months)_
- **Health beliefs associated with persistent symptoms** _(time frame: at inclusion, 3 months, 6 months)_

## Locations (1)

- Hôtel Dieu Hospital, Paris, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hôtel dieu hospital|paris||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05532904.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05532904*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*